Skip to main content

Table 3 Disease progression from LSIL to HSIL by HPV types

From: Enhanced disease progression due to persistent HPV-16/58 infections in Korean women: a systematic review and the Korea HPV cohort study

  N Progression Probability of progression within 36 months (95% CI)a Hazard ratio (95% CI) P valuec
Unadjusted Adjustedb
LSIL to HSIL 245 45 25.7 (18.3–32.3)    
Age
 20–29 59 10 22.5 (8.4–34.3) Ref Ref  
 30–39 71 17 30.6 (16.3–42.5) 1.30 (0.60–2.84) 1.30 (0.58–2.90) 0.520
 40–49 69 15 32.0 (15.8–45.0) 1.14 (0.51–2.53) 1.10 (0.49–2.48) 0.818
 50–59 46 3 10.5 (0.0–21.2) 0.34 (0.09–1.24) 0.39 (0.11–1.48) 0.167
HPV type at baseline
 Low-risk 104 8 10.9 (2.9–18.4) Ref Ref  
 HPV-16 49 17 45.2 (24.8–60.0) 4.69 (2.03–10.88) 4.71 (2.02–11.02) 0.001
 HPV-18 22 4 20.9 (0.3–37.3) 2.34 (0.71–7.78) 2.72 (0.81–9.13) 0.105
 HPV-31 12 2 16.7 (0.0–35.3) 3.08 (0.65–14.53) 2.87 (0.60–13.68) 0.186
 HPV-33 14 4 68.2 (0.0–92.8) 3.96 (1.19–13.18) 4.17 (1.25–13.94) 0.021
 HPV-45 9 1 11.1 (0.0–29.4) 1.59 (0.20–12.74) 2.96 (0.36–24.64) 0.316
 HPV-52 34 7 22.2 (6.1–35.5) 2.64 (0.96–7.29) 3.42 (1.23–9.52) 0.019
 HPV-58 51 15 43.1 (22.0–58.5) 4.17 (1.77–9.84) 4.37 (1.84–10.41) 0.001
Type-specific persistent infection 135 29 38.8 (22.4–51.7)    
 Low-risk 78 7 12.4 (2.8–21.0) Ref Ref  
 HPV-16 15 8 66.6 (20.5–85.9) 4.01 (1.45–11.10) 4.24 (1.49–12.10) 0.007
 HPV-18 5 1 20.0 (0.0–48.4) 2.04 (0.25–16.62) 2.25 (0.27–18.44) 0.451
 HPV-31 2 0 NA NA NA NA
 HPV-33 5 3 70.0 (0.0–93.7) 5.95 (1.53–23.09) 4.56 (1.165–18.04) 0.030
 HPV-45 1 0 NA NA NA NA
 HPV-52 12 2 9.1 (0.0–24.6) 1.49 (0.31–7.18) 1.81 (0.37–8.91) 0.464
 HPV-58 20 9 50.3 (17.0–70.3) 4.23 (1.58–11.37) 4.18 (1.54–11.33) 0.005
  1. ASCUS: Atypical squamous cells of uncertain significance; LSIL: Low-grade squamous intraepithelial lesion; HSIL: High-grade squamous intraepithelial lesion; 95% CI: 95% confidence interval
  2. aProbabilities of progression were estimated by Kaplan–Meier survival analysis
  3. bHazard ratios and 95% confidence intervals were adjusted by age and genotype
  4. cP-values were calculated in the adjusted analysis